Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 22Recurrence 4Neoplasms 3Plasmablastic Lymphoma 2Leukemia, Myeloid, Acute 2Smoldering Multiple Myeloma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Plasma Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Lenalidomide 2Dexamethasone 2Calcium Dobesilate 2iberdomide 1daratumumab 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × daratumumab × 30 days × Clear all
NCT03937635 2026-05-15

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Eastern Cooperative Oncology Group

Phase 3 Recruiting
288 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡